主动监测中磁共振成像试验的最终分析
这项单臂前瞻性试验纳入172例低危前列腺癌患者,以连续多参数磁共振成像替代确认性活检进行主动监测。中位随访69个月,无生化复发、转移和前列腺癌相关死亡分别为99.3%、100%和100%;作者认为在基线行磁共振靶向联合饱和模板活检的前提下,省略1年确认性活检风险极小,但仍应进行标准3年系统性活检。
要点
- 多参数磁共振成像检测进展为临床显著前列腺癌的敏感度为57%、特异度为82%。
- 多参数磁共振成像和前列腺特异性抗原密度均为进展的显著预测因素。
- 仅2.3%(4/172)患者出现假阴性多参数磁共振成像且伴高危病理特征。
核心结论
- 最终分析表明,若基线已行磁共振靶向联合饱和模板活检,主动监测中省略1年确认性活检风险极小,但因偶见磁共振不可见肿瘤,仍应进行标准3年系统性活检。
研究设计与样本
- 单臂前瞻性试验,共纳入172例适合主动监测的前列腺癌男性(Gleason 3+3=6或Gleason 3+4=7且Gleason 4模式总体≤10%且Gleason 4模式<2针)。
- 基线行多参数磁共振成像及模板±靶向活检,第1年和第2年行多参数磁共振成像,3年方案结束时行活检。
- 3年方案期间,若多参数磁共振成像异常和/或前列腺特异性抗原密度升高(>0.2 ng/ml/cc)则触发活检。
主要发现
- 多参数磁共振成像检测进展为临床显著前列腺癌的敏感度为57%(95%CI 39%-74%)、特异度为82%(95%CI 74%-89%)、阳性预测值为50%(95%CI 38%-62%)、阴性预测值为86%(95%CI 81%-90%)。
- 多参数磁共振成像(OR 6.20,95%CI 2.72-14.16,P<.001)和前列腺特异性抗原密度(OR 6.19,95%CI 2.14-17.92,P=.001)均为进展的显著预测因素。
- 仅2.3%(4/172)患者出现假阴性多参数磁共振成像且伴高危病理特征(pT3或高体积国际泌尿病理学会分级>2)。
- 全队列中位随访69个月(Q1-Q3 56-79)时,无生化复发、无转移和无前列腺癌相关死亡分别为99.3%、100%和100%。
临床怎么用
- 作者认为,在基线行磁共振靶向联合饱和模板活检的前提下,主动监测中省略1年确认性活检风险极小。
- 作者认为,由于偶见磁共振成像不可见肿瘤,应进行标准3年系统性活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to assess the medium-term oncologic outcomes of an active surveillance protocol, replacing confirmatory biopsy with serial multiparametric magnetic resonance imaging. MATERIALS AND METHODS: A total of 172 men were enrolled in this single-arm prospective trial. Men with prostate cancer (Gleason 3+3=6 or Gleason 3+4=7 with ≤10% Gleason pattern 4 overall and <2 cores Gleason pattern 4) eligible for surveillance were included in the study. Men underwent baseline multiparametric magnetic resonance imaging and template ± targeted biopsy, then multiparametric magnetic resonance imaging at years 1 and 2 with a 3-year end-of-protocol biopsy. Biopsies during the 3-year protocol period were triggered by abnormalities on multiparametric magnetic resonance imaging and/or increases in prostate specific antigen density (>0.2 ng/ml/cc). RESULTS: The sensitivity, specificity, positive predictive value, and negative predictive value of multiparametric magnetic resonance imaging to detect progression to clinically significant prostate cancer were 57% (95% CI 39%-74%), 82% (95% CI 74%-89%), 50% (95% CI 38%-62%), and 86% (95% CI 81%-90%), respectively. Both multiparametric magnetic resonance imaging and prostate specific antigen density were significant predictors for progression (multiparametric magnetic resonance imaging OR 6.20, 95% CI 2.72-14.16, P < .001; prostate specific antigen density OR 6.19, 95% CI 2.14-17.92, P = .001). Only 2.3% (4/172) of patients had false-negative multiparametric magnetic resonance imaging and high-risk pathological features (pT3 or high-volume International Society of Urological Pathology >2). After a median 69 months (Q1-Q3 56-79) follow-up of all patients in the cohort, freedom from biochemical recurrence, metastasis, and prostate cancer-related death were 99.3%, 100%, and 100%, respectively. CONCLUSIONS: Final analysis of the Magnetic Resonance Imaging in Active Surveillance trial indicates that there is minimal risk to omitting 1-year confirmatory biopsy during active surveillance if baseline magnetic resonance-targeted + saturation template biopsy was performed; however, standardized 3-year systematic biopsy should be performed due to occasional magnetic resonance imaging-invisible tumors.
引用
- Doan P, Scheltema MJ, Amin A, et al. Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial. J Urol. 2022. PMID: 35947521. doi:10.1097/JU.0000000000002885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。